Innovation Pharmaceuticals Inc.

Equities

IPIX

US45782D1000

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:29:09 2024-05-23 EDT			5-day change	1st Jan Change
0.0015 ^USD	0.00%		+15.38%	-69.39%

02-01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
2023	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020

February 22, 2021 at 11:20 am

Innovation Pharmaceuticals Inc. announced earnings results for the second quarter ended December 31, 2020. For the second quarter, the company announced operating loss was USD 3.439 million compared to USD 1.345 million a year ago. Net loss was USD 6.174 million compared to USD 2.625 million a year ago. For the half year, sales was USD 0 compared to USD 400,000 a year ago. Operating loss was USD 4.568 million compared to USD 2.286 million a year ago. Net loss was USD 7.347 million compared to USD 4.175 million a year ago.

Latest news about Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	02-01	CI
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	12-05	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-20	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	23-06-21	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	23-03-15	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-15	CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	22-12-13	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Innovation Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-09-27	CI
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical.	22-06-14	CI
Squalus Medical announced that it has received $4.999968 million in funding from Innovation Pharmaceuticals Inc., and other investors	22-06-08	CI
Innovation Pharmaceuticals Inc. announced a financing transaction	22-06-08	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-13	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-14	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-09	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-27	CI
Innovation Pharmaceuticals Provides Additional Information Regarding the Status of Its Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of Brilacidin for the Treatment of Moderate-To-Severe Covid-19 in Hospitalized Patients	21-08-12	CI
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting	21-07-22	CI
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium	21-06-18	CI
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19	21-06-03	CI
Innovation Pharmaceuticals Announces Patient Enrollment Reaches 90% in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for Covid-19	21-05-27	CI
Innovation Pharma Surpasses 50% Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19	21-04-28	CI

Chart Innovation Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Companyâs lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). It is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. It is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INNOVATION PHARMACEUTICALS INC.	-69.39%	794K
VERTEX PHARMACEUTICALS INCORPORATED	+10.83%	115B
REGENERON PHARMACEUTICALS, INC.	+12.53%	106B
BIONTECH SE	-4.21%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.51%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.29%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.56%	12.13B

Bio Therapeutic Drugs